To estimate the relevance of combining EV‐RNA and cfDNA signal in BrCa, we compared the classification performance of every single analyte (“only DNA”, “only RNA”) versus combined analytes (“combo OR”, “combo AND”, meaning that high level of either one or both analytes is required for positivity; see Methods) by focusing on the presence or absence of ERBB2 amplification or HER2 overexpression (see Method section HER2 positivity classification of plasma and tissue samples). The gene discussed is ERBB2; the disease is invasive breast carcinoma.